Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Neuroprotective Effects of the Nutraceutical Dehydrozingerone and its C2- symmetric Dimer in a Drosophila Model of Parkinson’s Disease

Maria Dolores Setzu
,
Ignazia Mocci
,
Davide Fabbri
ORCID logo ,
Paola Carta
ORCID logo ,
Patrizia Muroni
,
Andrea Diana
ORCID logo ,
Maria Antonietta Dettori
* ORCID logo ,
Maria Antonietta Casu
* ORCID logo
Version 1 : Received: 26 December 2023 / Approved: 27 December 2023 / Online: 27 December 2023 (09:49:17 CET)

A peer-reviewed article of this Preprint also exists.

Setzu, M.D.; Mocci, I.; Fabbri, D.; Carta, P.; Muroni, P.; Diana, A.; Dettori, M.A.; Casu, M.A. Neuroprotective Effects of the Nutraceutical Dehydrozingerone and Its C2-Symmetric Dimer in a Drosophila Model of Parkinson’s Disease. Biomolecules 2024, 14, 273. Setzu, M.D.; Mocci, I.; Fabbri, D.; Carta, P.; Muroni, P.; Diana, A.; Dettori, M.A.; Casu, M.A. Neuroprotective Effects of the Nutraceutical Dehydrozingerone and Its C2-Symmetric Dimer in a Drosophila Model of Parkinson’s Disease. Biomolecules 2024, 14, 273.

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of dopamin-ergic neurons responsible for unintended or uncontrollable movements. Mutations in leu-cine-rich repeat kinase 2 locus, contributes to genetic forms of PD. The fruit fly Drosophila mela-nogaster carrying this mutation (LRRK2-Dm), is an in vivo model of PD that develops motor impairment and stands for an eligible non mammalian paradigm to test novel therapeutic ap-proaches. Dehydrozingerone (DHZ) is a natural phenolic compound isolated from ginger. Pre-sents anti-inflammatory, antioxidant and neuroprotective properties making it a potential therapeutic target for PD. We administered DHZ and its C2-symmetric dimer (DHZ-DIM) at 0.5 and 1mM, for 14 and 21 days, in the LRRK2-Dm, with the aim to assess changes for rescuing motor behavior, brain dopaminergic neurons, mitochondria and synapses (T-Bars). The shorter treat-ment with both molecules revealed efficacy at the higher dose improving climbing behavior with a prevention of dopaminergic neuronal demise. After 21 days, a recovery of the motor disability, dopaminergic neuron loss, mitochondrial damage and T-Bars failure was observed with the DHZ-DIM. Our data indicates that the DHZ-DIM exerts a more potent neuroprotective effect respect to the monomer in LRRK2-Dm, prompting further investigation of these compounds in rodent models of PD.

Keywords

Parkinson’s Disease; nutraceutical compounds; dehydrozingerone; hydroxylated biphenyls, nat-ural compounds; Drosophila Melanogaster; LRRK2, neuroprotection

Subject

Biology and Life Sciences, Neuroscience and Neurology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.